Adaptimmune Therapeutics plc (NASDAQ: ADAP) announced that it has initiated a Phase I triple tumor study using its wholly owned ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE